

Tips for talking to your healthcare provider about the Prolaris® biopsy test

A good patient-clinician relationship should work like a partnership.

Take an active role in finding out which prostate cancer treatment is right for you.

Prostate cancer is personal, your treatment should be too. The Prolaris test provides personalized information about the aggressiveness of your cancer, helping you to know if you are safe to forego treatment or if you should pursue treatment. Here are some tips to help you build a partnership with your doctor to get your genomic insights and start the conversation about why every newly diagnosed man needs Prolaris.

Be prepared



Do your research on possible prostate cancer treatments, side-effects, and biomarker tests - like Prolaris. Come prepared to your cancer consultation with any information the doctor or staff may need to see. Make sure to bring along the *Prolaris Physician Ouick Guide*.

Be open and confident



First and foremost, remember that your doctor is on your side. You both want what's best for you, and helping you successfully manage your cancer is everyone's top priority. So just be open and honest about potential treatments or possible side-effects.

Bring your support team



The support of family members or close friends can help facilitate the conversation with your doctor and help act as a co-advocate for your care at your next appointment.

Discuss ordering the test



If you are ready for personalized genetic information to help you confidently make your treatment decision, ask your Urologist to order Prolaris today. Ordering is easy, your provider just needs to send the request form to Myriad and we take care of the rest

Myriad, the Myriad logo, Prolaris, the Prolaris logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.

© 2022 Myriad Genetics, Inc.

RCCPONEPGR/02-22

Use these tips to prepare for your upcoming appointment and share the accompanying materials with your doctor





Healthcare professional quick guide to the Prolaris® biopsy test

Your patient has downloaded these materials to help facilitate a discussion with you about ordering the Prolaris test to help inform their prostate cancer treatment plan.

What is Prolaris?

The Prolaris test from Myriad Genetics provides a personalized risk assessment of your patients' prostate cancer. Prolaris combines traditional clinical variables like PSA and Gleason with an independent molecular score to deliver the most prognostic information.^{1,7}

Prolaris advantage



Tumor biology improves initial treatment decisions for every man with prostate cancer



Reproducible studies provide confidence in receiving the most accurate results



2x more predictive than PSA and Gleason¹



Only test repeatedly proven to work in untreated patients 1,2,3,4

How to order:

- 1. Fill out the Prolaris Biopsy test request form or download one here:
- 2. Email test request form to Prolariscs@myriad.com or fax to 801-883-3256
- 3. Test results sent directly to provider's office in around 2 weeks



Learn more about our clinical utility and validity studies



Insurance coverage and financial assistance



Medicare covers at 100%




>93% of patients pay \$0




The Prolaris biopsy test report

The Prolaris Biopsy result shows a patient's risk in relation to two validation thresholds. These thresholds identify candidates for active surveillance (AS) based on 10-year Disease-Specific Morality (DSM) with conservative management and candidates for single- or multi-modal treatment based on 10-year metastasis (Mets) risk if treated.

- Men who are considered safe for active surveillance may be spared unnecessary treatment
- Men who are not considered safe for active surveillance are identified as candidates for single-modal therapy
- Men who are not considered safe to pursue singlemodal treatment are identified as candidates for multimodal therapy



S Risk when pursuing active treatment



Sources

¹Cuzick J, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. BJC 2012;106(6):1095-1099

²Lin, D.W., et al. Identification of Men with Low-Risk Biopsy-Confirmed Prostate Cancer AS Candidates for Active Surveillance. Urologic Oncology: Seminars and Original Investigations. 2018; DOI:10.1016/J. UROLONC.2018.03.011

³Kaul S, et al. Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score. Per Med. 2019;16(6):491 499. doi:10.2217/pme-2019-0084

⁴Cuzick J, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer 2015; 113:382–389

⁵Canter, C et al. Biopsy-delivered cell cycle progression score outperformed pathological upgrading or upstaging in predicting biochemical recurrence after surgery. Poster session presented at: Western AUA; 2018 October 28; Maui, HI

⁶https://prolaris.com/posters-and-medical-publications/#!#home

⁷Tward JD, et al. The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. International Journal of Radiation Oncology, Biology, Physics. 2021. DOI:https://doi. org/10.1016/j.ijrobp.2021.09.03

